Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.
The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
| Country | Israel |
| Founded | 1993 |
| IPO Date | May 15, 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 208 |
| CEO | Dror Bashan |
Contact Details
Address: Science Park, 2 Snunit St. Karmiel, 2161401 Israel | |
| Phone | 972 4 902 8100 |
| Website | protalix.com |
Stock Details
| Ticker Symbol | PLX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001006281 |
| CUSIP Number | 74365A309 |
| ISIN Number | US74365A3095 |
| Employer ID | 65-0643773 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dror Bashan | President, Chief Executive Officer and Director |
| Eyal Rubin M.B.A. | Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary |
| Yaron Naos | Senior Vice President of Operations |
| Yael Fellous | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| Jul 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 28, 2024 | 8-K | Current Report |
| May 17, 2024 | ARS | Filing |
| May 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |